Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Report 2026

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Overview

• Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors market size has reached to $10.96 billion in 2025 • Expected to grow to $16.35 billion in 2030 at a compound annual growth rate (CAGR) of 8.3% • Growth Driver: Rising Diabetes Prevalence Boosts Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor Market Growth • Market Trend: Innovations In SGLT2 Inhibitors For Enhanced Diabetes And Heart Failure Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?

Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of medications used to treat type 2 diabetes by blocking the SGLT2 protein in the kidneys, preventing glucose reabsorption and promoting its excretion in urine. This helps lower blood glucose levels and can also contribute to weight loss and reduced blood pressure. They have additional cardiovascular and renal benefits, making them valuable in managing diabetic complications. The main types of sodium glucose cotransporter 2 (SGLT 2) inhibitors are invokana, Jardiance, farxiga or forxiga, and suglat. Invokana refers to a prescription medication used to lower blood sugar levels in adults with type 2 diabetes. These medications are typically administered through the oral route and others and are used by end users such as hospitals, homecare settings, and clinics.

What Is The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Growth Forecast?

The sodium glucose cotransporter 2 (sglt2) inhibitors market size is expected to see strong growth in the next few years. It will grow to $16.35 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to cardio-renal benefit recognition, aging diabetic population, expanded reimbursement coverage, new drug launches, emerging market penetration. Major trends in the forecast period include expanded use beyond diabetes, increased combination therapy adoption, growth in heart failure indications, improved safety profiling, wider guideline inclusion.

What Is The Driver Of The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?

The increasing prevalence of diabetes is expected to propel the growth of the sodium glucose cotransporter 2 (SGLT2) inhibitor market going forward. Diabetes refers to a group of metabolic disorders characterized by high blood sugar levels resulting from defects in insulin secretion, insulin action, or both. The rise in diabetes cases can be attributed to factors such as urbanization, stress, environmental pollutants, and a lack of access to healthcare services. Sodium glucose cotransporter 2 (SGLT2) inhibitors are used in diabetes treatment to lower blood glucose levels by preventing glucose reabsorption in the kidneys, leading to its excretion in urine. They also offer cardiovascular and renal benefits, making them a valuable option for managing diabetes and its complications. For instance, in March 2025, according to the Office for Health Improvement and Disparities (OHID), UK-Based English government organization, the prevalence of type 2 diabetes recorded by GPs among adults aged 17 and over in England was 7.0% in March 2024, up from 6.8% in March 2023. Therefore, the increasing prevalence of diabetes is driving the growth of the sodium glucose cotransporter 2 (SGLT2) inhibitor industry.

Key Players In The Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

Major companies operating in the sodium glucose cotransporter 2 (sglt2) inhibitors market are Johnson & Johnson Inc., Merck & Co Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Astellas Pharma Inc, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co Ltd, Taisho Pharmaceutical Holdings Co Ltd, Lupin Limited, Glenmark Pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co Ltd, Kotobuki Pharmaceutical Co Ltd, Lexicon Pharmaceuticals Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Hanmi Pharmaceutical Co Ltd, Chong Kun Dang Pharmaceutical Corp, Mitsubishi Tanabe Pharma Corporation

Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Trends and Insights

Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitor market are focused on developing dual inhibitor therapeutic solutions to improve patient outcomes and manage blood sugar levels. Dual inhibitor therapeutic solutions refer to treatments that simultaneously target two different sodium-glucose cotransporters (SGLT1 and SGLT2) to enhance efficacy in managing conditions such as heart failure and diabetes. For instance, in May 2023, Lexicon Pharmaceuticals Inc., a US-based biopharmaceutical company, received approval from the Food and Drug Administration (FDA) for sotagliflozin, a treatment for heart failure. This first-in-class dual inhibitor of sodium-glucose cotransporters 1 and 2 is a once-daily tablet designed to reduce cardiovascular death, heart failure hospitalizations, and urgent heart failure visits in adults with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Its benefits include reduced renal glucose and sodium reabsorption, which leads to preload and afterload reduction and decreased sympathetic activity.

What Are Latest Mergers And Acquisitions In The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?

In October 2024, Viatris Inc., a US-based global healthcare company, entered into an exclusive licensing agreement with Lexicon Pharmaceuticals to commercialize sotagliflozin in all markets outside of the U.S. and Europe. The collaboration aims to expand access to sotagliflozin, enhance treatment options for patients with diabetes, and foster innovation in the global diabetes therapeutics market. Lexicon Pharmaceuticals is a US-based biopharmaceutical company specializing in the development of novel therapies for metabolic diseases.

What Defines the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?

The sodium glucose cotransporter 2 (SGLT2) inhibitors market consists of sales of luseogliflozin, remogliflozin, tofogliflozin and sergliflozin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Report 2026?

The sodium glucose cotransporter 2 (sglt2) inhibitors market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the sodium glucose cotransporter 2 (sglt2) inhibitors industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.